Clinical trial

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced…

NCT00420238 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00420238
Title Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
Official title A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Ankylosing Spondylitis
Intervention type Drug, Other
Interventions Etanercept (Enbrel), Placebo
Enrollment 82
Start date Jan 1, 2007
Primary completion Feb 1, 2009
Completion May 1, 2009
First posted Jan 11, 2007
Last update posted Jun 29, 2010
Countries France, Germany, Hungary, Netherlands

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies